Cynapsus Therapeutics Reports Third Quarter 2012 Financial

Cynapsus Therapeutics Reports Third Quarter 2012 Financial Results
and Recent Developments 
TORONTO, ONTARIO -- (Marketwire) -- 11/15/12 -- Cynapsus Therapeutics
Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing
the only non-injectable (i.e. sublingual) delivery of the only
approved drug (apomorphine) for the rescue of "off" episodes in
Parkinson's disease, today announced its results for the three and
nine months ended September 30, 2012. Unless specified otherwise, all
amounts are in Canadian dollars. 
"In the third quarter our team achieved one of our most important
accomplishments to date - a grant of USD $947,925 from The Michael J.
Fox Foundation (MJFF)," said Anthony Giovinazzo, President and Chief
Executive Officer of Cynapsus. "The ability of our team to meet the
MJFF's stringent internal and external review of our project is a
great achievement. With support from the MJFF, we will now study
APL-130277 in a more robust Comparative Biostudy (CTH-103). The
CTH-103 study is designed to mirror the design and conditions of our
registration Bioequivalence Study, but on a smaller scale. In order
to fund the Bioequivalence Study, the Company is currently working to
raise $7 million by way of a short form prospectus offering for
institutional investors. The closing is currently expected to be
completed on or about December 15, 2012. We look forward to reporting
further progress over the next 30 days." 
Financial Highlights 


 
--  Cash at September 30, 2012 of $287,188 (December 31, 2011: $294,812). 
--  On July 18, 2012, the Company announced the closing of a non-brokered
    private placement raising gross proceeds of $100,000. 
--  On August 8, 2012, the Company announced that it has been awarded a
    grant of USD $947,925 from the Michael J. Fox Foundation. Funds awarded
    by MJFF are to be used solely for the Comparative Biostudy and are
    conditioned by meeting certain milestones and deliverables. 
--  Subsequent to the end of the third quarter, on October 24, 2012, the
    Company announced the closing of a brokered private placement raising
    gross proceeds of $170,000. 
--  Net loss of $641,123 for the three months ended September 30, 2012
    (September 30, 2011: Net loss of $476,690) 
--  Report 140,887,219 common shares outstanding at September 30, 2012
    (December 31, 2011: 131,743,219). 

 
Recent Developments 
The following achievements were made during the quarter: 
Cynapsus was awarded a grant from The Michael J. Fox Foundation to
support clinical studies to develop APL-130277. On August 8, 2012 the
Company announced that it has been awarded a grant of USD $947,925
from the MJFF. The grant was awarded under the Foundation's Edmond J.
Safra Core Programs for Parkinson's Research, Clinical Intervention
Awards aimed at supporting human clinical trials testing promising
Parkinson's therapies that may significantly and fundamentally
improve treatment for people with Parkinson's.  
Cynapsus completed a second human volunteer pilot proof-of-concept
clinical trial (CTH-102) of APL-130277. The results of the first
study (CTH-101) were reported on January 10, 2012. The CTH-102 study
was closed out in August 2012 after it was determined that the goal
of finding a therapeutic dose had been reached. The first dose
evaluated in the study was deemed to be dose proportional to the dose
evaluated in the CTH-101 clinical pilot study and achieved a
pharmacokinetic profile (Cmax, AUC and Tmax) that was sufficiently
similar to subcutaneous injectable apomorphine. Management decided
that it was unnecessary to proceed with a second dose, and then began
preparations for a Comparative Biostudy (CTH-103) to be funded by the
MJFF. 
Cynapsus commenced activities for a Comparative Biostudy (CTH-103) of
APL-130277. In the third quarter, the Company began work on CTH-103,
a placebo-controlled, randomized cross-over Phase 1 trial in healthy
volunteers to examine the pharmacokinetic profile of multiple dose
strengths of APL-130277 as compared to equivalent doses of
apomorphine subcutaneous injection. The study is expected to be
completed in Q1 2013. The objective of this study is to directly
compare the pharmacokinetic profile of APL-130277 to subcutaneous
apomorphine in healthy subjects to more precisely design the
subsequent Bioequivalence Study. The Bioequivalence Study is expected
to be completed by the fall of 2013. 
Cynapsus signed a term sheet for a $7 million short form prospectus
offering. Based on efforts in the third quarter, on October 3, 2012,
the Company announced that it signed a term sheet with a Health Care
/ Life Sciences focused Institutional Investment Group to be the lead
investor in a short form prospectus offering of $7 million of its
common shares and warrants. The closing is expected to be completed
on or about December 15, 2012.  
Stock Option Grant 
Effective November 14, 2012, the Company granted stock options to
acquire 462,500 common shares. The stock options were granted to a
consultant of the Company at an exercise price equal to $0.10 per
share and with an expiry of 5 years.  
About Cynapsus Therapeutics 
Cynapsus is a specialty pharmaceutical company developing the only
non-injectable (i.e. sublingual) delivery of the only approved drug
(apomorphine) to be used as a rescue therapy for "off" motor symptoms
of Parkinson's disease. Over one million people in the U.S. and an
estimated 5 million people globally suffer from Parkinson's disease.
Parkinson's disease is a chronic and progressive neurodegenerative
disease that impacts motor activity, and its prevalence is increasing
with the aging of the population. Based on a recent study and the
results of the Company's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients
experience "off" episodes in which they have impaired movement or
speaking capabilities. Current medications only control the disease's
symptoms, and most drugs become less effective over time as the
disease progresses.  
Cynapsus' drug candidate, APL-130277, is an easy-to-administer,
fast-acting reformulation of apomorphine, which is approved in an
injection formulation to rescue patients from "off" episodes.
Cynapsus is focused on maximizing the value of APL-130277 by
completing pivotal studies in advance of a New Drug Application
expected to be submitted in 2015. Cynapsus anticipates a trade sale
or out-licensing to an appropriate global pharmaceutical partner
before such an application is submitted. 
More information about Cynapsus (TSX VENTURE:CTH) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis
and Retrieval (SEDAR) at www.sedar.com.  
Forward Looking Statements 
This announcement contains "forward-looking statements" within the
meaning of applicable Canadian securities legislation. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "plans", "expects" or "does not
expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might"
or "will be taken", "occur" or "be achieved". Forward-looking
statements are subject to known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity,
performance or achievements of Cynapsus to be materially different
from those expressed or implied by su
ch forward-looking statements,
including but not limited to those risks and uncertainties relating
to Cynapsus' business disclosed under the heading "Risk Factors" in
its Annual Information Form filed on November 1, 2012 and its other
filings with the various Canadian securities regulators which are
available online at www.sedar.com. Although Cynapsus has attempted to
identify important factors that could cause actual results to differ
materially from those contained in forward-looking statements, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such statements
will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on
forward-looking statements. Cynapsus does not undertake to update any
forward-looking statements, except in accordance with applicable
securities laws. 
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press release. 
Contacts:
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca 
Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca
www.cynapsus.ca